EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/224 |
| Summary: | Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions. |
|---|---|
| ISSN: | 1726-9776 1996-1812 |